Cargando…

External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)

BACKGROUND: Due to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD), the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper clinical and prognostic assessment, but not all of them were validated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Espantoso-Romero, Maite, Román Rodríguez, Miguel, Duarte-Pérez, Ana, Gonzálvez-Rey, Jaime, Callejas-Cabanillas, Pedro A., Lazic, Durdica Kasuba, Anta-Agudo, Berta, Torán Monserrat, Pere, Magallon-Botaya, Rosa, Gerasimovska Kitanovska, Biljana, Lingner, Heidrun, Assenova, Radost S., Iftode, Claudia, Gude-Sampedro, Francisco, Clavería, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106777/
https://www.ncbi.nlm.nih.gov/pubmed/27835945
http://dx.doi.org/10.1186/s12890-016-0305-2
_version_ 1782467119150006272
author Espantoso-Romero, Maite
Román Rodríguez, Miguel
Duarte-Pérez, Ana
Gonzálvez-Rey, Jaime
Callejas-Cabanillas, Pedro A.
Lazic, Durdica Kasuba
Anta-Agudo, Berta
Torán Monserrat, Pere
Magallon-Botaya, Rosa
Gerasimovska Kitanovska, Biljana
Lingner, Heidrun
Assenova, Radost S.
Iftode, Claudia
Gude-Sampedro, Francisco
Clavería, Ana
author_facet Espantoso-Romero, Maite
Román Rodríguez, Miguel
Duarte-Pérez, Ana
Gonzálvez-Rey, Jaime
Callejas-Cabanillas, Pedro A.
Lazic, Durdica Kasuba
Anta-Agudo, Berta
Torán Monserrat, Pere
Magallon-Botaya, Rosa
Gerasimovska Kitanovska, Biljana
Lingner, Heidrun
Assenova, Radost S.
Iftode, Claudia
Gude-Sampedro, Francisco
Clavería, Ana
author_sort Espantoso-Romero, Maite
collection PubMed
description BACKGROUND: Due to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD), the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper clinical and prognostic assessment, but not all of them were validated in an international primary care cohort, different from the original ones used for model development. Therefore, our main aim is to assess the prognostic capacity of the ADO, BODEx and DOSE indices in primary care for predicting mortality in COPD patients and to validate the models obtained in subgroups of patients, classified by revised Global Initiative for Chronic Obstructive Lung Disease (2011) and updated Spanish Guideline (2014). Besides, we want to confirm that the prognostic capacity of all indices increases if the number of exacerbations is substituted by the interval between them and to assess the impact on health of the patient’s lifestyle, social network and adherence to treatment. METHODS: Design: External validation of scales, open and prospective cohort study in primary care. Setting: 36 health centres in 6 European high, medium and low income countries. Subjects: 477 patients diagnosed with COPD, captured in clinical visit by their General Practitioner/Nurse. Predictors: Detailed patient history, exacerbations, lung function test and questionnaires at baseline. Outcomes: Exacerbations, all-cause mortality and specific mortality, within 5 years of recruitment. Analysis: Multivariate logistic regression and Cox regression will be used. Possible non-linear effect of the indices will be studied by using Structured Additive Regression models with penalised splines. Subsequently, we will assess different aspects of the regression models: discrimination, calibration and diagnostic precision. Clinical variables modulated in primary care and the interval between exacerbations will be considered and incorporated into the analysis. DISCUSSION: The Research Agenda for General Practice/Family Medicine highlights that the evidence on predictive values of prognostic indices in primary care is scarce. A prospective cohort like that of PROEPOC/COPD provides good opportunities for research into COPD and make communication easier between family practitioners, nursing staff, pneumologists and other professionals, supporting a multi-disciplinary approach to the treatment of these patients. TRIAL REGISTRATION: ISRCTN52402811. Date: 15/01/2015. Prospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-016-0305-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5106777
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51067772016-11-17 External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort) Espantoso-Romero, Maite Román Rodríguez, Miguel Duarte-Pérez, Ana Gonzálvez-Rey, Jaime Callejas-Cabanillas, Pedro A. Lazic, Durdica Kasuba Anta-Agudo, Berta Torán Monserrat, Pere Magallon-Botaya, Rosa Gerasimovska Kitanovska, Biljana Lingner, Heidrun Assenova, Radost S. Iftode, Claudia Gude-Sampedro, Francisco Clavería, Ana BMC Pulm Med Study Protocol BACKGROUND: Due to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD), the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper clinical and prognostic assessment, but not all of them were validated in an international primary care cohort, different from the original ones used for model development. Therefore, our main aim is to assess the prognostic capacity of the ADO, BODEx and DOSE indices in primary care for predicting mortality in COPD patients and to validate the models obtained in subgroups of patients, classified by revised Global Initiative for Chronic Obstructive Lung Disease (2011) and updated Spanish Guideline (2014). Besides, we want to confirm that the prognostic capacity of all indices increases if the number of exacerbations is substituted by the interval between them and to assess the impact on health of the patient’s lifestyle, social network and adherence to treatment. METHODS: Design: External validation of scales, open and prospective cohort study in primary care. Setting: 36 health centres in 6 European high, medium and low income countries. Subjects: 477 patients diagnosed with COPD, captured in clinical visit by their General Practitioner/Nurse. Predictors: Detailed patient history, exacerbations, lung function test and questionnaires at baseline. Outcomes: Exacerbations, all-cause mortality and specific mortality, within 5 years of recruitment. Analysis: Multivariate logistic regression and Cox regression will be used. Possible non-linear effect of the indices will be studied by using Structured Additive Regression models with penalised splines. Subsequently, we will assess different aspects of the regression models: discrimination, calibration and diagnostic precision. Clinical variables modulated in primary care and the interval between exacerbations will be considered and incorporated into the analysis. DISCUSSION: The Research Agenda for General Practice/Family Medicine highlights that the evidence on predictive values of prognostic indices in primary care is scarce. A prospective cohort like that of PROEPOC/COPD provides good opportunities for research into COPD and make communication easier between family practitioners, nursing staff, pneumologists and other professionals, supporting a multi-disciplinary approach to the treatment of these patients. TRIAL REGISTRATION: ISRCTN52402811. Date: 15/01/2015. Prospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-016-0305-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-11 /pmc/articles/PMC5106777/ /pubmed/27835945 http://dx.doi.org/10.1186/s12890-016-0305-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Espantoso-Romero, Maite
Román Rodríguez, Miguel
Duarte-Pérez, Ana
Gonzálvez-Rey, Jaime
Callejas-Cabanillas, Pedro A.
Lazic, Durdica Kasuba
Anta-Agudo, Berta
Torán Monserrat, Pere
Magallon-Botaya, Rosa
Gerasimovska Kitanovska, Biljana
Lingner, Heidrun
Assenova, Radost S.
Iftode, Claudia
Gude-Sampedro, Francisco
Clavería, Ana
External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
title External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
title_full External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
title_fullStr External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
title_full_unstemmed External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
title_short External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
title_sort external validation of multidimensional prognostic indices (ado, bodex and dose) in a primary care international cohort (proepoc/copd cohort)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106777/
https://www.ncbi.nlm.nih.gov/pubmed/27835945
http://dx.doi.org/10.1186/s12890-016-0305-2
work_keys_str_mv AT espantosoromeromaite externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT romanrodriguezmiguel externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT duarteperezana externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT gonzalvezreyjaime externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT callejascabanillaspedroa externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT lazicdurdicakasuba externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT antaagudoberta externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT toranmonserratpere externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT magallonbotayarosa externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT gerasimovskakitanovskabiljana externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT lingnerheidrun externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT assenovaradosts externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT iftodeclaudia externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT gudesampedrofrancisco externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT claveriaana externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort
AT externalvalidationofmultidimensionalprognosticindicesadobodexanddoseinaprimarycareinternationalcohortproepoccopdcohort